[Discriminant analysis of bone marrow suppression of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
Twenty-five patients with primary or metastatic brain tumor were treated with two administrations of MCNU, 67-125 mg/m2 i.v., at 1-293 day intervals. Thrombocytopenia of less than 10 X 10(4)/mm8 occurred in 9 cases (36.0%) and leukocytopenia of less than 3 X 10(3)/mm3 in 11 cases (44.0%). The factors influencing these two kinds of bone marrow suppression were investigated using discriminant analysis (SPSS software package). The most influential factor for thrombocytopenia was the dose of MCNU and that for leukocytopenia was the interval between the two administrations. These results show that patients should be able to receive this drug without suffering bone marrow suppression if care is taken with regard to their condition with the time interval between doses.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008433:Mathematics; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C020766:ranimustine